Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study
Table 2
Demographic and baseline characteristics of patients.
All patients (N = 158)
DLBCL (N = 72)
FL (N = 86)
Age (years)
Mean (SD)
58.7 (11.28)
59.7 (12.70)
57.8 (9.92)
Median (range)
59.5 (27–80)
61.0 (27–80)
56.5 (30–80)
Age category, n (%)
≥18 and ≤64
107 (67.7%)
42 (58.3%)
65 (75.6%)
>64 and ≤80
51 (32.3%)
30 (41.7%)
21 (24.4%)
Sex, n (%)
Male
86 (54.4%)
44 (61.1%)
42 (48.8%)
Female
72 (45.6%)
28 (38.9%)
44 (51.2%)
Ethnicity, n (%)
Hispanic
9 (5.7%)
4 (5.6%)
5 (5.8%)
Non-Hispanic
131 (82.9%)
59 (81.9%)
72 (83.7%)
Not applicable
3 (1.9%)
1 (1.4%)
2 (2.3%)
Other
15 (9.5%)
8 (11.1%)
7 (8.1%)
BMI (kg/m2)
Mean (SD)
26.2 (4.81)
25.3 (4.40)
27.0 (5.02)
Median (range)
25.8 (16.5–47.6)
25.8 (16.6–36.2)
25.9 (16.5–47.6)
ECOG performance status
Grade 0
107 (67.7%)
36 (50.0%)
71 (82.6%)
Grade 1
43 (27.2%)
30 (41.7%)
13 (15.1%)
Grade 2
7 (4.4%)
5 (6.9%)
2 (2.3%)
Missing
1 (0.6%)
1 (1.4%)
0 (0.0%)
IPI score
Low risk
28 (17.7%)
28 (38.9%)
-
Low intermediate risk
15 (9.5%)
15 (20.8%)
-
High intermediate risk
17 (10.8%)
17 (23.6%)
-
High risk
12 (7.6%)
12 (16.7%)
-
FLIPI Score
Low risk
25 (15.8%)
-
25 (29.1%)
Intermediate risk
32 (20.3%)
-
32 (37.2%)
High risk
29 (18.4%)
-
29 (33.7%)
Grade of FL
1
9 (5.7%)
-
9 (10.5%)
2
45 (28.5%)
-
45 (52.3%)
3a
32 (20.3%)
-
32 (37.2%)
N: number of patients; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; SD: standard deviation; BMI: body mass index; ECOG: Eastern Cooperative Oncology Group; IPI: International Prognostic Index; FLIPI: Follicular Lymphoma International Prognostic Index.
